Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2025-12-27 @ 6:48 AM
Study NCT ID:
NCT01297894
Status:
UNKNOWN
Last Update Posted:
2011-12-29
First Post:
2011-02-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Colistin Versus Colistin Plus Fosfomycin for Infections Caused by MDR Acinetobacter Baumannii
Sponsor:
Mahidol University
Organization:
Study Overview
Official Title:
Colistin Plus Fosfomycin in Multi-Drug Resistant Acinetobacter Baumannii
Status:
UNKNOWN
Status Verified Date:
2011-12
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In Siriraj Hospital, colistin alone for treatment of MDR A. baumannii contributed to mortality 45% Fosfomycin is an antimicrobial which has activity against gram-negative bacterial including MDR A. baumannii In this study, we compare the clinical and microbiologicalresponse of colistin alone versus colistin plus fosfomycin in treatment of A. baumannii infected patients
Detailed Description:
Inclusion criteria
* Age\> 18 years
* Hospitalized to Siriraj Hospital
* Infected caused by A. baumannii
* Need Colistin treatment
Exclusion criteria
* Pregnancy or Lactating mother
* Colistin or Fosfomycin Allergy
* Patients who have severe abnormal renal or liver function
* Age\> 18 years
* Hospitalized to Siriraj Hospital
* Infected caused by A. baumannii
* Need Colistin treatment
Exclusion criteria
* Pregnancy or Lactating mother
* Colistin or Fosfomycin Allergy
* Patients who have severe abnormal renal or liver function
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: